NCT06476366View on ClinicalTrials.gov

Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 14, 2024

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions
Chronic Actinic Dermatitis
Interventions
DRUG

Azathioprine

azathioprine will be started at 0.3mg/kg orally daily. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking TPMT levels)

DRUG

Methotrexate

Methotrexate will be started at 5mg/week and dose escalated by 2.5mg weekly to ultimately 10mg/week. Tablet Folic acid 0.5mg will be given orally daily, skipping the day of methotrexate

Trial Locations (1)

Unknown

Pak Emirates Military Hospital, Rawalpindi

All Listed Sponsors
lead

Pak Emirates Military Hospital

OTHER

NCT06476366 - Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial | Biotech Hunter | Biotech Hunter